Sherry Korczynski - 09 Sep 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Chief Commercial Officer
Issuer ticker: AQST
Reported as of: 09 Sep 2026
Net transaction value: -$45,675
SEC form: 4
Accepted by SEC: 11 Sep 2026, 11:07:53 UTC
Prior SEC filing: 17 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas Zalewski, as Attorney-In-Fact

Key filing fact

Sherry Korczynski filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 11 Sep 2026.

Key facts

This page summarizes Sherry Korczynski's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Sep 2026, 11:07.

Change

Previous filing in this sequence was filed on 17 Aug 2026.
Current net transaction value: -$45,675.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002026090 Primary reporting owner

Korczynski Sherry

Relationship: Chief Commercial Officer
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Thomas Zalewski, as Attorney-In-Fact
Signature date: 11 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,750
Change %: +3.7%
Price: $2.65^*
Shares after: 244,439
Date: 09 Sep 2026
Ownership: Direct

AQST transaction

Common Stock

Sale

Transaction value: $45,675
Shares: -8,750
Change %: -3.6%
Price: $5.22
Shares after: 235,689
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -8,750
Change %: -25%
Price: $0.000000^*
Shares after: 26,250
Date: 09 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,750
Exercise price: $2.65
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.

Footnote F2

The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.